Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era

American Cancer Society. Key statistics about kidney cancer. https://www.cancer.org/cancer/kidney-cancer/about/key-statistics.html. Surveillance, Epidemiology and End Results Program. Cancer stat facts: kidney and renal pelvis cancer. https://seer.cancer.gov/statfacts/html/kidrp.html. Sternberg, 2010, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial, J Clin Oncol, 28, 1061, 10.1200/JCO.2009.23.9764 Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Rini, 2011, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, Lancet, 378, 1931, 10.1016/S0140-6736(11)61613-9 Choueiri, 2015, Cabozantinib versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1814, 10.1056/NEJMoa1510016 Rini, 2019, Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1116, 10.1056/NEJMoa1816714 Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126 Motzer, 2019, Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1103, 10.1056/NEJMoa1816047 National Comprehensive Cancer Network. Kidney cancer version 4.2022. Plymouth meeting, PA: NCCN; 2021. Gan, 2021, Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials, Eur J Cancer, 151, 115, 10.1016/j.ejca.2021.04.004 Doshi, 2021, Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab, J Clin Oncol, 39, 305, 10.1200/JCO.2020.39.28_suppl.305 Brown, 2021, Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab, J Immunother Cancer, 9, e003281, 10.1136/jitc-2021-003281 The US Oncology Network. https://usoncology.com/. Friends of Cancer Research. Considerations for use of real-world evidence in oncology. https://friendsofcancerresearch.org/wp-content/uploads/Use_of_Real-World_Evidence_in_Oncology_0-1.pdf. Martin, 2022, Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician’s choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma, EJHaem, 3, 97, 10.1002/jha2.312 Zakharia, 2020, 34P Patient characteristics and treatment patterns in advanced renal cell carcinoma (aRCC): following introduction of new therapies, Ann Oncol, 31, S1429, 10.1016/j.annonc.2020.10.521 Shaw, 2021, Second-line therapies in the changing landscape of first-line therapies for metastatic clear cell renal cell cancer, Oncology, 35, 306, 10.46883/ONC.2021.3506.0306 George, 2021, Real-world treatment patterns and sequencing for metastatic renal cell carcinoma (mRCC): results from the Flatiron database, J Clin Oncol, 39, 286, 10.1200/JCO.2021.39.6_suppl.286 Geynisman, 2021, Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma (mRCC) using real-world data, J Clin Oncol, 39, 288, 10.1200/JCO.2021.39.6_suppl.288 Zakharia, 2022, Real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States, J Clin Oncol, 40, 314, 10.1200/JCO.2022.40.6_suppl.314 Walker, 2021, Comparisons of real-world time-to-event end points in oncology research, JCO Clin Cancer Informatics, 5, 45, 10.1200/CCI.20.00125 Friends of Cancer Research. Establishing a framework to evaluate real-world endpoints. https://www.focr.org/sites/default/files/pdf/RWE_FINAL%207.6.18.pdf. Gong, 2018, Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): a pooled analysis of 8 trials, J Clin Oncol, 36, 9064, 10.1200/JCO.2018.36.15_suppl.9064 Blumenthal, 2019, Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer, Ann Oncol, 30, 830, 10.1093/annonc/mdz060 Mori, 2021, Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis, Cancer Immunol Immunother, 70, 265, 10.1007/s00262-020-02684-8 Elaidi, 2020, Comparative efficacy of first-line immune-based combination therapies in metastatic renal cell carcinoma: a systematic review and network meta-analysis, Cancers, 12, 1673, 10.3390/cancers12061673 Choueiri, 2018, Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update, Eur J Cancer, 94, 115, 10.1016/j.ejca.2018.02.012 Gan, 2021, Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): results from the International mRCC Database Consortium (IMDC), J Clin Oncol, 39, 276, 10.1200/JCO.2021.39.6_suppl.276 Zarrabi KK, Handorf E, Miron B, et al. Comparative effectiveness of front-line ipilimumab and nivolumab or axitinib and pembrolizumab in metastatic clear cell renal cell carcinoma. Oncologist. In press. https://doi.org/10.1093/oncolo/oyac195.